OLANZAPINE TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

OLANZAPINE

제공처:

JUBILANT GENERICS LIMITED

ATC 코드:

N05AH03

INN (국제 이름):

OLANZAPINE

복용량:

20MG

약제 형태:

TABLET

구성:

OLANZAPINE 20MG

관리 경로:

ORAL

패키지 단위:

30/100/1000

처방전 유형:

Prescription

치료 영역:

ATYPICAL ANTIPSYCHOTICS

제품 요약:

Active ingredient group (AIG) number: 0128783006; AHFS:

승인 상태:

APPROVED

승인 날짜:

2014-01-16

제품 특성 요약

_Pr_
_Olanzapine _
_Page 1 of 55 _
PRODUCT MONOGRAPH
PR
OLANZAPINE
Olanzapine Tablets
2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg
Manufacturer Standard
Antipsychotic Agent
MANUFACTURER:
Jubilant Generics Limited
1-A, Sector -16A, Institutional Area,
Noida -201301, Uttar Pradesh, India
DATE OF REVISION: April 7, 2020
IMPORTER AND DISTRIBUTOR:
Pharmapar Inc.
1565 boul. Lionel-Boulet,
Varennes QC J3X 1P7
SUBMISSION CONTROL NO: 237756
_Pr_
_Olanzapine _
_Page 2 of 55 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL
USE............................................................................3
CONTRAINDICATIONS
................................................................................................4
WARNINGS AND
PRECAUTIONS...............................................................................4
ADVERSE
REACTIONS...............................................................................................13
DRUG INTERACTIONS
...............................................................................................26
DOSAGE AND
ADMINISTRATION............................................................................28
OVERDOSAGE
.............................................................................................................29
ACTION AND CLINICAL PHARMACOLOGY
.........................................................30
STORAGE AND
STABILITY.......................................................................................32
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................32
PART II: SCIENTIFIC INFORMATION
........................................................................33
PHARMACEUTICAL
INFORMATION.....................................................................33
CLINICAL
TRIALS..........................................................................